# Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

> **NCT00364611** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 73 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00364611
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-06
- **Final completion:** 2012-04
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364611, "Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00364611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*